PTC Therapeutics (PTCT) Misses Q3 EPS by 22c, Revenue Beats
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Far-left party wins Berlin election, pledging to nationalise housing
- Anthropic and Accenture partner on embedded AI safety evaluation
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
PTC Therapeutics Provides a Corporate Update and Reports Third Quarter Financial Results
October 27, 2022 4:03 PM EDT- Total quarterly revenue of $217 million, representing 57% year-over-year growth -- 2022 DMD revenue guidance and low end of total revenue guidance increased -- Strategic financing with Blackstone with up to $1 billion of low-cost, low-dilution capital -- Pipeline of multiple innovative compounds continues to advance in clinical development -
SOUTH PLAINFIELD, N.J., Oct. 27, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and financial results for the third quarter ending September 30, 2022.Â
... More